Skip to Content

Posts tagged with "Drug Development"

  • Business and Markets

    Nivien’s Shot

    Have you ever heard of Nivien Therapeutics? Unless you follow the oncology world pretty closely, probably not. But they are – well, were – a startup out of Harvard that was working on a promising approach to overcoming chemotherapy resistance in pancreatic cancer. Now that’s what we call an “unmet medical need”, consid… Read More
  • Drug Assays

    A Magic Methyl, Spotted in the Wild

    You hear medicinal chemists talking about the “magic methyl”, the big effect that a single CH3 group can have on potency or selectivity. Here’s a new J. Med. Chem. paper that shows one in action.That structure looks like a kinase inhibitor if anything ever did, and so it is. But small changes to it can… Read More
  • Drug Assays

    Ligand Efficiency Rethought

    Peter Kenny has a paper out on ligand efficiency that’s required reading for medicinal chemists using (or thinking about) that concept as a design tool. I’d recommend reading it with this recent paper – between the two of them, you’re going to have references to a huge swath of the literature on how to measure… Read More
  • Cancer

    A Nobel for Immuno-Oncology

    As many had expected, the Nobel prize in medicine/physiology this year recognizes advances in immuno-oncology: James Allison (for CTLA4) and Tasuku Honjo (PD-1). For some years now, that has been a huge, massive, unstoppable wave in cancer research, and I would not want to try to estimate how much time, effort, and money has gone… Read More
  • Drug Assays

    A New Antibiotic? Yes, Please

    New antibiotics against resistant Gram-negative bacteria make me happy, so I’m very glad to see this report from Genentech. They’ve been doing a lot of work on an antibiotic scaffold (arylomycins, Update: on a program that came in whey they bought RQx) which had not thus far really found much practical use, and it looks… Read More
  • Clinical Trials

    Digging Into the Genetics of Drug Targets

    Rare diseases – remember years ago, back when those were a case of market failure? When companies were reluctant to work on them because the market size was guaranteed to be small and you’d have to charge, like, a hundred thousand or more a year to make the whole idea financially viable? Which wasn’t going… Read More
  • Business and Markets

    Anarchist Drugs For All. Yeahboy.

    I’ve had numerous requests for my opinion about this article, so here it comes: it’s largely bullshit. It’s about “a volunteer network of anarchists and hackers developing DIY medical technologies”, and I can see why Vice.com is running the article, because that drugs/anarchists/hackers combo is absolute catnip to thei… Read More
  • Drug Development

    On Jadedness

    It’s a Friday in midsummer, so I assume that a fair percentage of the readership is not even around! So I’m not going to do a huge detailed blog post (got one of those coming on Monday, actually). Today I just wanted to go on a bit about a problem that comes with experience in… Read More
  • Alzheimer's Disease

    The Case of Verge Genomics

    A number of people have passed along the recent press stories about Verge Genomics, a new company out of YCombinator that has just raised $32 million for neuroscience drug discovery. Now that, as literally anyone who’s ever done it can tell you, is a hard field of a hard field, and I wish Verge good… Read More
  • Analytical Chemistry

    The Entropic Term is Laughing At Us

    There are plenty of things to optimize in a med-chem project other than binding affinity. But if you don’t have at least some level of binding, you may not have a med-chem project. And while from the outside, you might think that understanding how and why compound A binds to a given target while compound… Read More
123...